Monte Rosa Therapeutics logo
Startup

Monte Rosa Therapeutics

See Monte Rosa Therapeutics's full profile

BOOK A DEMO
Headquarters

Switzerland

Founded Year

2020

Total Funding

$128.5M

Employees

51 - 200

Status

Active


About Monte Rosa Therapeutics

Every cell has evolved sophisticated machinery to regulate the expression and function of proteins by degradation. This elaborate mechanism involves the controlled ubiquitination of protein substrates by E3 ligase complexes.

Headquarters

Switzerland


General Information on Monte Rosa Therapeutics

Brand name Monte Rosa Therapeutics
Company name Monte Rosa Therapeutics AG
Website https://www.monterosatx.com/
Founded year 2020
Employees 51 - 200
Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Monte Rosa Therapeutics

StreetInsider 15.08.2022
Jefferies Starts Monte Rosa Therapeutics (GLUE) at Buy

August 15, 2022 3:27 AM EDT Jefferies analyst Kelly Shi initiates coverage on Monte Rosa Therapeutics (NASDAQ ... This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE Member Login

Monte Rosa Therapeutics news
Com-Unik 15.08.2022
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns Buy Rating from Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group began coverage on shares of Monte Rosa Therapeutics ( NASDAQ:GLUE – Get Rating in a note issued to investors on Monday, Briefing.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Jefferies Financial Group's price objective would indicate a potential upside of 95.89% from the company's previous close. GLUE has been the subject of several other research reports. Piper ...

Monte Rosa Therapeutics news
Marketscreener DE 15.08.2022
Monte Rosa Therapeutics, Inc. : Jefferies & Co. behält seine Kaufempfehlung bei | MarketScreener

Monte Rosa Therapeutics, Inc. : Jefferies Co. behält seine Kaufempfehlung bei © MarketScreener mit MT Newswires 2022 Alle Nachrichten zu MONTE ROSA THERAPEUTICS, INC. News auf Englisch zu MONTE ROSA THERAPEUTICS, INC. Analystenempfehlungen zu MONTE ROSA THERAPEUTICS, INC. ...

Monte Rosa Therapeutics news
TheFly 15.08.2022
Monte Rosa Therapeutics initiated with a Buy at Jefferies

Hot Stocks ShowHide Related Items  08:05 Today Unity rejects proposal from AppLovin, reaffirms commitment to ironSource deal 08/11/22 Unity wins three-year contract from CACI 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/12/22 DA Davidson AppLovin price target lowered to $70 from $80 at DA Davidson 08/11/22 Credit ...

Monte Rosa Therapeutics news
The Pawtucket Times 13.08.2022
Monte Rosa Therapeutics: Q2 Earnings Snapshot

BOSTON (AP) _ Monte Rosa Therapeutics Inc. (GLUE) on Thursday reported a loss of $26.5 million in its second quarter. The Boston-based company said it had a loss of 57 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 54 cents per share.

Market Screener 12.08.2022
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022

Monte Rosa Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2022. For the second quarter, the company reported net loss was USD 26.47 million compared to USD 18.41 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 3.63 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to USD 3.63 a year ago. © S&P Capital IQ 2022

Monte Rosa Therapeutics news
Finanzen 12.08.2022
Monte Rosa Therapeutics präsentierte Quartalsergebnisse

Monte Rosa Therapeutics lud am 11.08.2022 zur Finanzkonferenz und hat dort die Zahlen zum am 30.06.2022 abgelaufenen Jahresviertel präsentiert. Das Ergebnis je Aktie fiel negativ aus. Der Verlust je Papier wurde auf 0,570 USD beziffert. Im Vorjahresviertel waren -3,630 USD je Aktie in den Büchern gestanden. Redaktion finanzen.at

Market Screener 12.08.2022
Monte Rosa Therapeutics : Corporate Presentation - August 2022

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | August 2022 Forward-Looking Statements These materials include express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as ...

Monte Rosa Therapeutics news
Finanzen.ch 12.08.2022
Monte Rosa Therapeutics: Bilanzzahlen zum vergangenen Quartal

Monte Rosa Therapeutics hat am 11.08.2022 die Geschäftsergebnisse zum am 30.06.2022 abgelaufenen Quartal offengelegt. Es wurde ein Verlust je Aktie in Höhe von 0.570 USD vermeldet. Im Vorjahresvergleich waren -3.630 USD erwirtschaftet worden. Redaktion finanzen.ch Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Finanzen.net 12.08.2022
Monte Rosa Therapeutics hat Bilanz für das abgelaufene Quartal gezogen

Monte Rosa Therapeutics Inc Registered Shs 9,16 USD Monte Rosa Therapeutics äußerte sich am 11.08.2022 zu den Geschäftsergebnissen des am 30.06.2022 abgelaufenen Quartals. Es wurde ein Verlust je Aktie in Höhe von 0,570 USD vermeldet. Im Vorjahresvergleich waren -3,630 USD erwirtschaftet worden. Redaktion finanzen.net Ausgewählte Hebelprodukte auf Monte Rosa Therapeutics Inc Registered Shs Mit Knock-outs können spekulative Anleger ...

Monte Rosa Therapeutics news